Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice

被引：1

作者：

Bertoli, Sarah ^{[1
]}

Tavitian, Suzanne ^{[1
]}

Delabesse, Eric ^{[2
,3
]}

Sarry, Audrey ^{[1
]}

Huguet, Francoise ^{[1
]}

Recher, Christian ^{[1
,4
]}

机构：

[1] Inst Univ Canc Toulouse Oncopole CHU Toulouse, Serv Hematol, Toulouse, France

[2] CHU Toulouse, Laboratoire Hematol, Toulouse, France

[3] CNRS, Hematol Lab, ERL5294, UMR1037 INSERM, Toulouse, France

[4] CNRS, Ctr Recherches Cancerol Toulouse, ERL5294, UMR1037 INSERM, Toulouse, France

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.1718.1718

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1718

引用

页数：6

共 50 条

[21] IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
C D DiNardo
E Jabbour
F Ravandi
K Takahashi
N Daver
M Routbort
K P Patel
M Brandt
S Pierce
H Kantarjian
G Garcia-Manero
Leukemia, 2016, 30 : 980 - 984
[22] The clinical use of IDH1 and IDH2 mutations in gliomas
Picca, Alberto
Berzero, Giulia
Di Stefano, Anna Luisa
Sanson, Marc
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2018, 18 (12) : 1041 - 1051
[23] IDH1 and IDH2 mutations in pediatric acute leukemia
A K Andersson
D W Miller
J A Lynch
A S Lemoff
Z Cai
S B Pounds
I Radtke
B Yan
J D Schuetz
J E Rubnitz
R C Ribeiro
S C Raimondi
J Zhang
C G Mullighan
S A Shurtleff
B A Schulman
J R Downing
Leukemia, 2011, 25 : 1570 - 1577
[24] Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors
Largeaud, Laetitia
Berard, Emilie
Bertoli, Sarah
Dufrechou, Stephanie
Prade, Nais
Gadaud, Noemie
Tavitian, Suzanne
Bories, Pierre
Luquet, Isabelle
Sarry, Audrey
De Mas, Veronique
Huguet, Francoise
Delabesse, Eric
Recher, Christian
LEUKEMIA RESEARCH, 2019, 81 : 82 - 87
[25] IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
DiNardo, C. D.
Jabbour, E.
Ravandi, F.
Takahashi, K.
Daver, N.
Routbort, M.
Patel, K. P.
Brandt, M.
Pierce, S.
Kantarjian, H.
Garcia-Manero, G.
LEUKEMIA, 2016, 30 (04) : 980 - 984
[26] IDH1 and IDH2 mutations in pediatric acute leukemia
Andersson, A. K.
Miller, D. W.
Lynch, J. A.
Lemoff, A. S.
Cai, Z.
Pounds, S. B.
Radtke, I.
Yan, B.
Schuetz, J. D.
Rubnitz, J. E.
Ribeiro, R. C.
Raimondi, S. C.
Zhang, J.
Mullighan, C. G.
Shurtleff, S. A.
Schulman, B. A.
Downing, J. R.
LEUKEMIA, 2011, 25 (10) : 1570 - 1577
[27] IDH1 and IDH2 Mutations Detected by Pyrosequencing in Cholangiocarcinoma
Voss, J. S.
Kerr, S. E.
Fritcher, E. G. Barr
Highsmith, W. E.
Zhang, J.
Roberts, L. R.
Gores, G. J.
Halling, K. C.
Kipp, B. R.
LABORATORY INVESTIGATION, 2012, 92 : 184A - 184A
[28] Mutations of IDH1 and IDH2 are not frequent in Multiple Myeloma
Langer, C.
Ibanez, M.
Liebisch, P.
Zenz, T.
Knop, S.
Einsele, H.
Paschka, P.
Doehner, H.
Doehner, K.
ONKOLOGIE, 2011, 34 : 159 - 159
[29] IDH1 and IDH2 Mutations Detected by Pyrosequencing in Cholangiocarcinoma
Voss, J. S.
Kerr, S. E.
Fritcher, E. G. Barr
Highsmith, W. E.
Zhang, J.
Roberts, L. R.
Gores, G. J.
Halling, K. C.
Kipp, B. R.
MODERN PATHOLOGY, 2012, 25 : 184A - 184A
[30] OUTCOME OF PATIENTS WITH REFRACTORY OR RELAPSED AML WITH IDH1 AND IDH2 MUTATIONS AFTER CONVENTIONAL SALVAGE THERAPY: A STUDY OF THE GERMAN-AUSTRIAN AML STUDY GROUP (AMLSG)
Paschka, P.
Schlenk, R.
Weber, D.
Horst, H. A.
Ringhoffer, M.
Khoene, C. H.
Held, G.
Kuendgen, A.
Goetze, K.
Brossart, P.
Greil, R.
Luebbert, M.
Wattad, M.
Rummel, M. J.
Heuser, M.
Gaidzik, V. I.
Teleanu, V.
Thol, F.
Goehring, G.
Ganser, A.
Doehner, K.
Doehner, H.
HAEMATOLOGICA, 2016, 101 : 326 - 326

← 1 2 3 4 5 →